0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Her2

Her2

Her2 Molecule Information

Name:Receptor protein-tyrosine kinase erbB-2
Target Synonym:HER2 ;Tyrosine kinase-type cell surface receptor HER2;MLN19;Metastatic lymph node gene 19 protein;ERBB2;Proto-oncogene Neu;p185erbB2;CD_antigen=CD340;Proto-oncogene c-ErbB-2;MLN 19;NEU;Receptor tyrosine-protein kinase erbB-2;NGL
Number of Launched Drugs:20
Number of Drugs in Clinical Trials:169
Lastest Research Phase:Approved

Her2 Protein Product ListCompare or Buy

Her2 Molecule Synonym Name

ERBB2,CD340,HER-2/neu,HER2,MLN19,NEU,NGL,TKR1

Her2 Molecule Background

Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer,communication at the neuromuscular junction andregulation of cell growth and differentiation .

Her2 References

Her2 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Trastuzumab biosimilar (Biocad) BCD-022 Approved Biocad Breast cancer Details
Afatinib Dimaleate BIBW-2992; BIBW-2992-MA2,BIBW 2992,BIBW2992 Approved Boehringer Ingelheim GILOTRIF fda Non small cell lung cancer (NSCLC), Metastatic squamous non-small cell lung cancer (NSCLC) BOEHRINGER INGELHEIM 2013-07-12 Non small cell lung cancer (NSCLC), Metastatic squamous non-small cell lung cancer (NSCLC) Details
Trastuzumab biosimilar (Zydus) Approved Zydus cadila Breast cancer Details
Trastuzumab RO45-2317; Anti-HER2/neu-MAb; MKC-454; R-597; RG-597; huMAb4D5-8 Approved Genentech, Chugai HERCEPTIN fda Gastric cancer, Breast cancer GENENTECH 1998-09-25 Gastric cancer, Breast cancer Details
Trastuzumab/Hyaluronidase-oysk Approved Genentech HERCEPTIN HYLECTA fda GENENTECH INC 2019-02-28 Metastatic breast cancer Details
Trastuzumab biosimilar (Reliance Life Sciences) R-TPR-016 Approved Reliance Life Sciences Breast cancer Details
Trastuzumab biosimilar (AXXO) Approved AXXO Breast cancer Details
Trastuzumab biosimilar (Celltrion) CT-P06; CT-P6,CTP06; CTP6 Approved Celltrion, Nippon Kayaku, Teva trastuzumab ema Celltrion Healthcare Hungary Kft. 2018-02-08 Gastric cancer, Breast cancer Details
Trastuzumab biosimilar (Allergan/Amgen) ABP-980,ABP980; ABP 980 Approved Synthon, Allergan, Daiichi Sankyo, Amgen trastuzumab ema Amgen Europe B.V., Breda 2018-05-16 Gastric cancer, Breast cancer Details
Neratinib Maleate CAN-030; HKI-272; PB-272; PF-0528767; WAY-179272 Approved Pfizer, Puma Biotechnology, CANbridge Life Sciences NERLYNX fda HER2-positive metastatic breast cancer PUMA BIOTECH 2017-07-17 HER2-positive metastatic breast cancer Details
Lapatinib Ditosylate Hydrate GW-572016F; GW-572016; GW-2016,GW572016,GW 572016F,GW572016F,GW 572016 Approved GlaxoSmithKline, Novartis TYKERB fda Breast cancer NOVARTIS 2007-03-13 ER positive metastatic breast cancer, HR-negative/HER2-positive metastatic breast cancer, Breast cancer, HER2-positive metastatic breast cancer, HER2-positive advanced breast cancer Details
Trastuzumab biosimilar (Dr. Reddy's Laboratories) Approved Dr Reddys Laboratories Breast cancer Details
Trastuzumab biosimilar (Biocon/Mylan) Bmab-200; Myl-1401O; HerMyl-1401O Approved Biocon, Mylan OGIVRI fda MYLAN GMBH 2017-12-01 Gastric cancer, Breast cancer, Gastroesophageal junction adenocarcinoma Details
Ado-trastuzumab emtansine T-DM1; PRO-132365; R-3502; RG-3502; RO-5304020 Approved Genentech, Chugai KADCYLA fda Breast cancer GENENTECH 2013-02-22 Breast cancer, HER2-positive metastatic breast cancer Details
Trastuzumab biosimilar (Samsung Bioepis) SB-3,SB3,SB 3 Approved Samsung Bioepis, Merck Sharp & Dohme, C-Bridge Capital Partners trastuzumab ema Samsung Bioepis NL B.V. 2017-11-15 Gastric cancer, Breast cancer Details
Trastuzumab biosimilar (AryoGen Pharmed) Approved AryoGen Biopharma Gastric cancer, Breast cancer Details
Dacomitinib PF-00299804; PF-299; PF-299804; PF-804; PF-00299804-03; PF-00299804-3,PF00299804,PF299804,PF299 Approved Pfizer, SFJ pharmaceuticals VIZIMPRO fda Non small cell lung cancer (NSCLC) PFIZER INC 2018-09-27 Non small cell lung cancer (NSCLC) Details
Pertuzumab rhuMab-2C4; R-1273; RG-1273; RO-4368451-F01; RO-4368451 Approved Genentech, Chugai PERJETA fda Breast cancer GENENTECH 2012-06-08 Breast cancer, HER2-positive metastatic breast cancer Details
Pyrotinib Maleate SHR-1258; BLTN; HTI-1001 Approved Jiangsu Hengrui Medicine Pyrotinib Maleate Tablets cfda HER2-positive metastatic breast cancer 2018-08-12 HER2-positive metastatic breast cancer Details
Trastuzumab biosimilar (Pfizer) PF-05280014; PF-5280014,PF05280014; PF5280014 Approved Pfizer trastuzumab ema Pfizer Europe MA EEIG 2018-07-26 Gastric cancer, Breast cancer Details

Her2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
IDN-6439 IDN-6439 Preclinical Indena Head and neck cancer Details
Trastuzumab glyco-optimised (Glycotope) GT-Mab-7.3-GEX Phase Ⅰ Glycotope Gastric cancer, Breast cancer Details
Anti-HER2 small molecule imaging agent (Affibody) 68GaABY025; ABY-002; ABY-0125; ABY-025 Phase Ⅲ Affibody Breast cancer Details
Trastuzumab biosimilar (Intas Pharmaceuticals) Phase Ⅲ Intas Biopharmaceuticals Breast cancer Details
AVA-006 AVA-006 Phase Not Specified Avacta Group, Glythera, Avacta Group, Glythera Cancer Details
Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) Phase Ⅰ National Cancer Institute Solid tumours Details
ADCT 502 (ADC Therapeutics) ADCT-502 Phase Ⅰ Cancer Research Technology, ADC Therapeutics Solid tumours Details
Trastuzumab biosimilar (Hualan Biological Engineering) Phase Ⅰ Hualan Biological Engineering Metastatic gastric carcinoma, Metastatic breast cancer Details
Trastuzumab biosimilar (BIOCND/Genor Biopharma) GB-221,GB221 Phase Ⅲ Genor Biopharma Breast cancer Details
Trastuzumab biosimilar (BioIntegrator) BI-Mab-03 Phase Ⅰ BioIntegrator Breast cancer Details
AU-101 AU-101 Phase Ⅱ Aurora BioPharma Breast cancer, Osteosarcoma, Glioblastoma Details
RG-6194 RG-6194; BTRC-4017A Phase Ⅰ Roche Solid tumours Details
Pirotinib Hydrochloride KBP-5209,KBP5209 Phase Ⅱ XuanZhu Pharma Non small cell lung cancer (NSCLC), Breast cancer, Lung cancer Details
HER2p63-71 peptide vaccine (Mie University) Phase Ⅰ Mie University Cancer Details
MEDI-4276 MEDI-4276 Phase Ⅰ MedImmune Gastric cancer, Breast cancer Details
RG-6148 DHES-0815A; RG-6148 Phase Ⅰ Roche HER2-positive breast cancer Details
Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) Phase Ⅰ Qilu Pharmaceutical Breast cancer Details
Mubritinib TAK-165,TAK165 Phase Ⅰ Takeda Breast cancer Details
Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical) HS-022 Preclinical Hisun Pharm Breast cancer Details
Trastuzumab biosimilar (CTTQ Pharma) Phase Ⅰ Chiatai Tianqing (CTTQ) Breast cancer Details
CP-724714 CP-724714 Phase Ⅱ Pfizer Metastatic breast cancer Details
111In-CHxADTPA-trastuzumab (Center for Cancer Research, Leidos Biomedical Research Inc/National Institutes of Health) Phase Ⅱ National Institutes of Health Diagnostic agents Details
Varlitinib Ditosylate ARRY-334543; ARRY-543; ASLAN-001; QBT-01; SPS-4370 Phase Ⅲ Array BioPharma Gastric cancer, Breast cancer, Solid tumours, Hepatocellular carcinoma (HCC), Pancreatic cancer, Biliary cancer Details
LCB14-0110 LCB14-0110; FS-1502 Phase Ⅰ LegoChemBio, Fosun Pharma Gastric cancer, Breast cancer, Solid tumours Details
Anti-HER2 ribozyme (Elan/Sirna) Phase Ⅰ Elan Pharm, Merck Breast cancer, Ovarian cancer Details
Margetuximab MGAH-22,MGAH22 Phase Ⅲ MacroGenics, Green Cross, Zai Lab Gastric cancer, HER2-positive metastatic breast cancer Details
Trastuzumab biosimilar (Hanwha Biologics) HD-201 BLA Filing Hanwha Biologics, Prestige BioPharma, Mundipharma Gastric cancer, oesophageal cancer, Breast cancer Details
NJH-395 NJH-395,NJH 395,NJH395 Phase Ⅰ Novartis Cancer Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase Ⅱ Shanghai Allist Pharmaceuticals Breast cancer, Lung cancer Details
PX-1031 (Pharmexa) PX-1031; PX-103.1; ME-103.1.1; ME-103 Phase Ⅱ Pharmexa Breast cancer Details
trastuzumab biosimilar (Hetero) Ado-Trastuzumab biosimilar (Hetero) Phase Ⅲ Hetero Drugs Cancer Details
AC-480 AC-480; BMS-599626 ,AC480; BMS599626 ,AC 480; BMS 599626 Phase Ⅰ Ambit biosciences Glioma, Solid tumours Details
Cancer vaccine (Merck & Co/Vical) V-930; V-932,V932,V930 Phase Ⅰ Merck Sharp & Dohme, Vical Non small cell lung cancer (NSCLC), Breast cancer, Colorectal cancer, Ovarian cancer Details
MRG002 MRG-002 Phase Ⅰ Shanghai Miracogen Gastric cancer, Breast cancer Details
Tucatinib ARRY-380; ONT-380 Phase Ⅲ Array BioPharma, Cascadian Therapeutics Breast cancer, Colorectal cancer Details
GB-251 GB-251,GB251 Phase Ⅰ Genor Biopharma HER2-positive metastatic breast cancer Details
Ertumaxomab Phase Ⅱ Trion Pharma, NeoPharm Breast cancer Details
HER2.taNK NK-92/5.28.z Phase Ⅰ NantKwest Glioblastoma Details
CUDC-101 CUDC-101,CUDC101 Phase Ⅰ Curis Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Hepatocellular carcinoma (HCC), Head and neck cancer Details
HER-2/HER-1 vaccine (Ohio State University) Phase Ⅰ Ohio State University Solid tumours Details
SHR-A1201 SHR-A1201 Phase Ⅰ Jiangsu Hengrui Medicine HER2-positive metastatic breast cancer Details
Larotinib Mesylate Z-650 Phase Ⅱ HEC Pharm Esophagus cancer Details
TAK-285 TAK-285,TAK285 Phase Ⅰ Takeda Solid tumours Details
Trastuzumab/Pertuzumab RG-6264; RO-7198574 Phase Ⅲ Roche, Chugai Breast cancer Details
Trastuzumab biosimilar (Bionovis/The Instituto Vital Brazil) Phase Not Specified Bionovis, The Instituto Vital Brazil Gastric cancer, Breast cancer, Metastatic breast cancer Details
KSP-910638-G KSP-910638-G; KSP-910638G Phase Ⅰ University of Michigan Gastrointestinal cancer Details
Pertuzumab biosimilar (Shanghai Henlius Biotech) HLX-11,HLX11 IND Filing Shanghai Henlius Biotech Breast cancer, Metastatic breast cancer Details
Pelitinib EKB-569; WAY-EKB-569,EKB569,WAY EKB569 Phase Ⅱ Pfizer Non small cell lung cancer (NSCLC), Colorectal neoplasms Details
Iodine-131-SGMIB anti-HER2 monoclonal antibody 131I-SGMIB-anti-HER2-VHH1; [131I]-SGMIB Anti-HER2-VHH1; CAM-H2; Iodine-131-SGMIB-anti-HER2-VHH1 Phase Ⅰ Camel-IDS Breast cancer Details
Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) B-003 (Shanghai Pharma) Phase Ⅰ Shanghai Pharma, Shanghai Jiaolian HER2-positive breast cancer Details
Disitamab Vedotin (Shijiazhuang Zhongqi Pharmaceutical) Phase Ⅰ Shijiazhuang Zhongqi Pharmaceutical HER2-positive advanced breast cancer Details
GBR-1302 GBR-1302; HBM-9302 Phase Ⅱ Glenmark Pharmaceuticals, Harbour BioMed Breast cancer Details
Trastuzumab biosimilar (NeuClone/Serum Institute of India) Phase Ⅰ NeuClone, Serum Institute of India Gastric cancer, Breast cancer Details
Sapitinib AZD-8931 Phase Ⅱ AstraZeneca Colorectal cancer Details
ALT-P7 HM2-MMAE; ALT-P7 Phase Ⅰ Alteogen, 3SBio Gastric cancer, Breast cancer Details
AE-37/GP-2 vaccine AE-37 (Generex Biotechnology Corporation) Phase Ⅱ Generex Biotechnology Corporation Prostate cancer, Breast cancer Details
KN-026 KN-026 Phase Ⅱ Alphamab Gastric cancer, Breast cancer Details
BMS-690514 BMS-690514,BMS690514 Phase Ⅱ Bristol-Myers Squibb Non small cell lung cancer (NSCLC), Breast cancer Details
A-166 A-166,A166 Phase Ⅱ Kelun Pharmaceutical Gastric cancer, HER2-positive breast cancer Details
HER2(EQ)BBzeta/CD19 T cells (City of Hope) Phase Ⅰ Mustang Bio, City of Hope National Medical Center Glioma Details
ADXS-31164 ADXS31-164; ADXS-31164; ADXS-cHER2; ADXS-HER2 Phase Ⅰ University of Pennsylvania, Advaxis Solid tumours, Osteosarcoma Details
Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) SIBP-01 Phase Ⅲ Shanghai Institute of Biological Products Breast cancer, Metastatic gastric carcinoma, Metastatic breast cancer Details
GB-235 GB-235,GB235 Phase Ⅰ Genor Biopharma HER2-positive breast cancer Details
Trastuzumab biosimilar (STC Biologics) STC-101 Phase Ⅰ STC Biologics Solid tumours Details
MP-412 AV-412; MP-412,MP412,AV412 Phase Ⅱ Mitsubishi Tanabe Pharma Solid tumours Details
Hemay-022 Hemay-022,Hemay022 Phase Ⅰ Tianjin Hemay Biotech, Xia Jiang Hemay Pharmaceutical HER2-positive breast cancer Details
Recombinant anti-HER2 antibody (Anke Biotech) Phase Ⅲ Anke Biotechnology Breast cancer Details
Selatinib Ditosilate QLNC-120,QLNC120 Phase Ⅱ Qilu Pharmaceutical, Qilu Antibiotics (Linyi) Pharmaceutical Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer Details
Recombinant anti-HER2 antibody-Tub114 DX126-262; DAC-001 Phase Ⅰ Hangzhou DAC Biotech HER2-positive breast cancer, Solid tumours Details
ICT-140 ICT-140 Preclinical ImmunoCellular Therapeutics Ovarian cancer Details
AEE-788 AEE-788; NVP-AEE-788,AEE788,NVPAEE788 Phase Ⅱ Novartis Glioblastoma multiforme Details
TAA-013 TAA-013,TAA013; TAA 013 Phase Ⅰ TOT Biopharm HER2-positive breast cancer, Solid tumours Details
Anti-CD3-anti-HER2-activated T cells Phase Ⅱ TransTarget, Barbara Ann Karmanos Cancer Institute, National Cancer Institute Breast cancer Details
Trastuzumab biosimilar (Tanvex Biopharma) TX-05 Phase Ⅲ Tanvex BioPharma Breast cancer Details
Anti-HER2 antibody toxin conjugate (TopoTarget) Phase Ⅰ Novartis, Topotarget Cancer Details
Trastuzumab duocarmazine SYD-985,SYD985; SYD 985 Phase Ⅲ Synthon Gastric cancer, Breast cancer, Solid tumours Details
ETBX-021 ETBX-021 Phase Ⅰ Etubics Corporation, NantBioScience Breast cancer Details
[89Zr]-Df-Trastuzumab Phase Ⅰ University of Alabama at Birmingham Breast cancer Details
Multi-epitope HER2 peptide vaccine (Mayo Clinic) Phase Ⅰ Mayo Clinic Breast cancer Details
AMX-3009 Maleate AMX-3009; AMX3009马来酸 Phase Ⅰ Arromax Pharmatech Gastric cancer, HER2-positive breast cancer, Pancreatic cancer Details
TT-16 TT-16 Preclinical Tessa Therapeutics Head and neck cancer Details
Recombinant human ErbB3 fragment vaccine (Zensun) rhErbB3-f Phase Ⅰ Zensun Solid tumours Details
Tesevatinib EXEL-7647; KD-019; KD-020; XL-647,KD019,EXEL7647,KD020,XL647 Phase Ⅲ Exelixis, Kadmon Non small cell lung cancer (NSCLC), Autosomal dominant polycystic kidney disease (ADPKD) Details
Trastuzumab biosimilar (United BioPharma) UB-921 Phase Ⅰ United BioPharma Breast cancer Details
Recombinant anti-HER2 humanized monoclonal antibody-DM1 (Qilu Pharmaceutical) Phase Ⅰ Qilu Pharmaceutical Breast cancer Details
TPIV-100 (TapImmune) TPIV-100 Phase Ⅱ Mayo Clinic, TapImmune Breast cancer Details
CIDeCAR Phase Ⅰ Bellicum, National Cancer Institute Solid tumours, Osteosarcoma Details
IBPM002BZ (Inbiopro Solutions) IBPM-002BZ Phase Not Specified Inbiopro Solutions Small cell lung cancer (SCLC), Renal cell carcinoma, Colorectal cancer Details
MP-0274 CME-114; SPA-28; MP-0274; CME-119; CME-118; CME-115; DARPin-41 Phase Ⅰ Molecular Partners Solid tumours Details
XMT-1522 TAK-522; XMT-1522,TAK 522 Phase Ⅰ Mersana Therapeutics, Adimab, Takeda Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer Details
anti-HER2 ADC (Pfizer) PF-06804103 Phase Ⅰ Pfizer Solid tumours Details
Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) Phase Ⅰ Seattle Children's Research Institute Central nervous system tumors Details
99m-Tc labeled anti-HER2 single domain antibody (NanoMab) 99mTc-NM-02 Phase Ⅰ NanoMab Technology Ltd Breast cancer Details
HER2 cancer vaccine (BioLife Science) IMU-131; PEV-6A; PEV-6,IMU 131; PEV 6A; PEV 6,IMU131; PEV6A; PEV6 Phase Ⅱ Pevion Biotech, Imugene, Mymetics Corporation Gastric cancer, Esophagus cancer, Breast cancer Details
BAT-8001 BAT-8001 Phase Ⅲ Bio-Thera Solutions Solid tumours, Metastatic breast cancer Details
ARX-788 ARX-788 Phase Ⅰ Ambrx, Zhejiang Medicine Solid tumours Details
PB-357 PB-357 Phase Ⅰ Pfizer Solid tumours Details
Trastuzumab deruxtecan DS-8201; DS-8201a BLA Filing Daiichi Sankyo, Bristol-Myers Squibb, Puma Biotechnology, AstraZeneca Breast cancer Details
Recombinant anti-HER2 subdomain II humanized monoclonal antibody (Livzon Group) LZM-005 Phase Ⅰ Livzon Group Livzon Pharmaceutical Factory HER2-positive metastatic breast cancer, HER2-positive breast cancer Details
HLX-22 AC-101; HLX-22 Phase Ⅰ AbClon, Shanghai Henlius Biotech Gastric cancer, Breast cancer Details
重组人源化抗HER2单克隆抗体(喜康生物) IND Filing JHL Biotech Solid tumours Details
IBPM003TZ (Inbiopro Solutions) IBPM-003TZ Phase Not Specified Inbiopro Solutions Breast cancer Details
HER-2 peptide-expressing DNA vaccine (Karolinska Institute) Phase Ⅰ Karolinska Institutet (KI) Cancer Details
tgDCC-E1A gene therapy (Targeted Genetics) Phase Ⅱ Targeted Genetics Breast cancer, Ovarian cancer, Head and neck cancer Details
MVA-BN-HER2 PX-1032; PX-103.2 Phase Ⅱ Pharmexa, Bavarian Nordic Breast cancer Details
AU-105 AU-105 Phase Ⅱ Aurora BioPharma Glioblastoma multiforme Details
Trastuzumab biosimilar (EirGenix) EG-12014 Phase Ⅲ EirGenix Breast cancer Details
DZD9008 DZD9008,DZD-9008 Phase Ⅰ Dizal (Jiangsu) Pharmaceutical Advanced non small cell lung cancer Details
SHR-1309 SHR-1309,SHR1309 Phase Ⅰ Jiangsu Hengrui Medicine HER2-positive metastatic breast cancer Details
PKI-166 CGP-75166; PKI-166; PKI-75166 Phase Ⅱ Novartis Solid tumours Details
Sirotinib Maleate XZP-5491,XZP5491 Phase Ⅰ XuanZhu Pharma Esophageal squamous cell carcinoma, Non small cell lung cancer (NSCLC), Gastric cancer Details
Trastuzumab biosimilar CMAB-809 Phase Ⅰ Taizhou Mabtech Gastric cancer, Breast cancer Details
Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) Phase Ⅰ Shenzhen Main Luck Pharmaceuticals Breast cancer Details
BVAC-B vaccine (Cellid) BVAC-B Phase Ⅰ Cellid Company Gastric cancer Details
M-802 M-802,M802; M 802 Phase Ⅰ YZY Bio Gastric cancer, HER2-positive breast cancer Details
Recombinant anti-HER2 humanized monoclonal antibody complex B-002,B002 Phase Ⅰ Shanghai Pharma HER2-positive breast cancer Details
Sym-013 Sym-013,Sym 013,Sym013 Phase Ⅱ Symphogen Cancer Details
Recombinant humanized anti-EGFR monoclonal antibody (Hisun Pharm/Mabworks Biotech) HS627 Phase Ⅰ Beijing Mabworks Biotech, Hisun Pharm Breast cancer Details
Trastuzumab biosimilar (Shanghai CP Guojian) CMAB-302 BLA Filing Shanghai CP Guojian Breast cancer Details
212 Pb-trastuzumab Phase Ⅰ Areva Pharmaceuticals, University of Alabama at Birmingham, University of Cincinnati Metastatic cancer Details
Trastuzumab biosimilar (Gedeon Richter) Preclinical Gedeon Richter, STADA Arzneimittel Gastric cancer, Breast cancer Details
Her-2 vaccine (University of Alabama/Galenica Pharmaceuticals) Phase Ⅰ University of Alabama at Birmingham, Adjuvantys Breast cancer Details
Trastuzumab biosimilar (BioXpress Therapeutics) BX-2318 Phase Not Specified BioXpress Therapeutics SA Breast cancer Details
Trastuzumab biosimilar (Alteogen) ALT-02; ALT-L2; ALT-LS2 Phase Ⅰ Alteogen, Cristalia, Qilu Pharmaceutical Breast cancer, Metastatic gastric carcinoma, HER2-positive metastatic breast cancer, Gastroesophageal junction adenocarcinoma Details
Recombinant HER2 humanized monoclonal antibody -DM1 conjugate (Shanghai CP Guojian Pharmaceutical) IND Filing Shanghai CP Guojian Unspecified Details
Gancotamab (Merrimack) MM-302 Phase Ⅲ Merrimack, Baxter, Johnson & Johnson Breast cancer Details
MDX H210 Phase Ⅱ Medarex Prostate cancer, Breast cancer Details
HER2/neu peptide vaccine (Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) Phase Ⅱ Fred Hutchinson/University of Washington Cancer Consortium HER2-positive breast cancer Details
Prolanta(Oncolix) Phase Ⅰ Oncolix Fallopian tube cancer, Prostate cancer, Breast cancer, Solid tumours, Peritoneum cancer, Ovarian cancer Details
IBI315 IBI-315; IBI315 Phase Ⅰ Innovent Biologics, Hanmi Cancer Details
HER2-antigen specific cancer vaccine HER2-ASCI Phase Ⅱ GlaxoSmithKline Breast cancer Details
IDM-1 IDM-1; MAK/IDM-1; MDX-210/MAK cells Phase Ⅲ Takeda Ovarian cancer Details
Lapatinib/Pazopanib Phase Ⅲ GlaxoSmithKline Renal cell carcinoma Details
MM-111 MM-111 Phase Ⅱ Merrimack Gastric cancer, Esophagus cancer, Breast cancer, Solid tumours Details
Canertinib Dihydrochloride CI-1033; PD-0183805; PD-183805 ,CI1033, PD 0183805,PD 183805 Phase Ⅱ Pfizer Non small cell lung cancer (NSCLC), Breast cancer, Ovarian cancer, Head and neck cancer Details
Cipatinib Tosylate SHR-1086 Phase Ⅰ Hansoh Pharma, Shanghai Pharma Breast cancer, Lung cancer Details
BMS-986186 BMS-986186; FS-102 Phase Ⅰ F-star, Bristol-Myers Squibb Gastric cancer, Breast cancer, Solid tumours Details
HER2/neu cancer vaccine (University of Washington/Corixa/GSK) Phase Ⅱ University of Washington, GlaxoSmithKline Breast cancer Details
AP-32788 TAK-788; AP-32788 Phase Ⅱ Takeda, Millennium Pharmaceutical, Ariad Non small cell lung cancer (NSCLC) Details
ZW-49 ZW-49 Phase Ⅰ Zymeworks, BeiGene Gastric cancer, Breast cancer, Solid tumours Details
Zenocutuzumab MCLA-128 Phase Ⅱ Merus Non small cell lung cancer (NSCLC), Gastric cancer, Solid tumours, Metastatic breast cancer, Ovarian cancer Details
Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) Phase Ⅰ Beijing Mabworks Biotech, Hisun Pharm Breast cancer Details
Pertuzumab biosimilar (CTTQ) Phase Ⅰ Chiatai Tianqing (CTTQ) HER2-positive metastatic breast cancer Details
Autologous-HER2-specific-T-cells Autologous-HER2-specific-T-cells Phase Ⅰ Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System Sarcoma Details
TGFBeta-resistant-HER2-EBV-CTLs TGFBeta-resistant-HER2-EBV-CTLs Phase Ⅰ Baylor College of Medicine, Methodist Hospital System Malignancies Details
TAS-0728 TAS-0728; TPC-107 Phase Ⅱ Taiho Pharma Solid tumours Details
Tarloxotinib Bromide TH-4000; PR-610; SN-33999 Phase Ⅱ Threshold Non small cell lung cancer (NSCLC) Details
BCD-147 BCD-147 Phase Ⅰ Biocad Unspecified Details
VB-7756 (Sesen Bio) VB-7756 Preclinical Viventia Biotech, Sesen Bio Cancer Details
Bispecific monoclonal antibody 2B1 Phase Ⅰ Chiron Cancer Details
Epertinib S-222611,S222611 Phase Ⅱ Shionogi Solid tumours Details
MBS-301 MBS-301 Phase Ⅰ Beijing Mabworks Biotech Gastric cancer, Breast cancer, Solid tumours Details
MB-103 MB-103 Phase Ⅰ City of Hope National Medical Center, Mustang Bio Glioblastoma, Brain metastases Details
Breast cancer vaccine HER-2/neu (GlaxoSmithKline) Phase Ⅱ GlaxoSmithKline Breast cancer Details
HS-10182 HS-10182,HS10182 Phase Ⅰ Hansoh Pharma Solid tumours Details
MX-402 MX-402,MX 402,MX402 Phase Ⅰ MedVax Technologies Gastric cancer Details
Lapuleucel-T APC-8024; BA-7072; DN-2402 Phase Ⅱ Dendreon Corporation Urogenital cancer Details
ZW-25 ZW-25 Phase Ⅱ Zymeworks, BeiGene Fallopian tube cancer, Gllbladder cancer, Gastric cancer, Esophagus cancer, Breast cancer, Colorectal cancer, Ovarian cancer, Cervical carcinoma, Biliary cancer Details
Pertuzumab biosimilar (NeuClone) Preclinical NeuClone Breast cancer, HER2-positive metastatic breast cancer Details
Trastuzumab biosimilar (Dong-A ST/Meiji Seika Pharma) DA-3111; DMB-3111 Phase Ⅰ Dong-A Pharmaceutical, Meiji Seika Pharma Gastric cancer, Breast cancer Details
Poziotinib HM-78136; HM-78136B; NOV1201; NOV-120101 Phase Ⅱ Hanmi, Luye Pharma, Spectrum Pharmaceuticals Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Head and neck cancer Details
Trastuzumab conjugate (BioIntegrator) BI-CON-02 Phase Ⅰ BioIntegrator Breast cancer Details
HER.CAR-CMV-specific-CTLs HER.CAR-CMV-specific-CTLs Phase Ⅰ Baylor College of Medicine, Methodist Hospital System, Texas Children's Hospital Glioblastoma multiforme Details
Trastuzumab biosimilar (Shanghai Henlius Biotech) HLX-02 BLA Filing Shanghai Henlius Biotech, Accord Healthcare Breast cancer Details
Trastuzumab biosimilar (Harbin Pharmaceutical Group) IND Filing Harbin Pharmaceutical Group Breast cancer Details
GP2 peptide vaccine (Cancer InSight) Phase Ⅰ Cancer Insight Breast cancer Details
MT-5111 (Molecular Templates) MT-5111 IND Filing Molecular Templates Breast cancer Details
Disitamab Vedotin (Yantai Rongchang Biological Engineering) RC48-ADC; RC-48; RC-48-ADC Phase Ⅱ Yantai Rongchang Biological Engineering, Remegen Gastric cancer, Urothelial cancer, HER2-positive metastatic breast cancer Details
Recombinant humanized anti-HER2 antibody (Hisun Pharma) Phase Ⅰ Hisun Pharm HER2-positive metastatic breast cancer Details
MDX-210 MDX-210 Phase Ⅱ Takeda Prostate cancer, Breast cancer, Colorectal cancer, Renal carcinoma Details
CP-347589 CP-347589 Phase Not Specified Pfizer Cancer Details
HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) Phase Ⅱ University of Pennsylvania, National Cancer Institute Breast cancer Details

This web search service is supported by Google Inc.

totop